Stocktoria
Celularity Inc CELU
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-23
Celularity Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Gross profit | — | — | $6.8M | -$1.7M | $11.7M |
| R&D expense | $15.0M | $17.4M | $30.5M | $78.4M | $88.4M |
| SG&A expense | $51.3M | $58.6M | $50.6M | $66.0M | $71.3M |
| Operating income | -$61.3M | -$38.4M | -$192.3M | -$25.6M | -$109.1M |
| Income tax | $3,000 | — | $10,000 | $13,000 | $20,000 |
| Net income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| EPS (diluted) | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-1.49 |
| Operating cash flow | -$13.3M | -$6.4M | -$38.7M | -$137.9M | -$110.1M |
| Free cash flow | — | -$6.6M | -$39.7M | -$143.1M | -$116.3M |
| Cash & equivalents | $6.2M | $738,000 | $227,000 | $14.0M | $37.2M |
| Inventory | $571,000 | $5.4M | $5.8M | $5.3M | $9.5M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M |
| Shareholders' equity | -$38.1M | $8.8M | $41.0M | $198.9M | $99.4M |
Source: SEC EDGAR filings · CIK 0001752828 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.